Trial Condition(s):
Multiple Sclerosis
Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis
Bayer Identifier:
308272
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
The purpose of this follow-up study is to look carefully at the long-term course of multiple sclerosis (MS) and possibly the long-term effects of Betaseron in the patients who were previously enrolled in the original North American study that led to the marketing approval of Betaseron.
Inclusion Criteria
- Patients in North America have to have been previously enrolled in the original Betaseron trial from 1988-1993 - Be able to understand the consent form (or have a guardian who can)
Exclusion Criteria
- North American patients cannot be included if they have not participated in the original Betaseron trial from 1988-1993
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | |
|---|---|
Locations Investigative Site Many Locations, Canada | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Canada | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Canada | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, United States | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, United States | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, United States | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, United States | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, United States | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, United States | Contact Us: E-mail: [email protected] Phone: Not Available |
Trial Design
A long-term follow up of patients enrolled in the pivotal study of Betaseron® (interferon beta 1b) in relapsing-remitting multiple sclerosis
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1
Primary Outcome
- Description of long term course of diseaseTimeframe: 16 years
Secondary Outcome
- Comparison to natural history cohortTimeframe: 16 years
Additional Information
Copyright © Bayer
Powered by
